Emerging Biotech Access Programme | #PHLEX

A limited number of €599 delegate passes are available for emerging biotech and biopharma companies preparing for commercial launch.

The programme is designed to ensure emerging biopharma companies are represented within the Pharma Launch Excellence community, giving launch teams access to the people, experience and partners relevant to successful commercialisation.

To qualify, your company must:

Meet the eligibility criteria? Secure your €599 delegate pass.

Who is not eligible?

Vendors, solution providers, consultancies and other organisations selling products or services into pharmaceutical or biotech companies are not eligible.

Subsidiaries, business units or affiliated companies belonging to larger corporate groups with 500 or more employees globally are not eligible, regardless of their individual company headcount. This includes organisations owned or controlled by established pharmaceutical companies.

Eligibility is assessed at the ultimate parent company level and is subject to organiser verification.

Join the PHLEX community.

If your company meets the criteria, register for the Emerging Biotech Access Programme at €599.